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SS-B/Lais a nuclear protein that isone ofthe target antigens ofautoantibodies
found in the sera of patients with SLE and Sjogren's syndrome (1, 2), and is
transiently associated with a number of small RNA species in the form of
ribonucleoprotein particles (3, 4). The SS-B-associated RNA species include
RNA polymerase III transcripts such as precursors oftRNA and 5S RNA, VA
RNA, EBER RNA, 4.5 RNA, 4.51 RNA, 7S RNA, Y RNA, and U6 RNA (3-
11). In addition, it has been reported that SS-B/La binds to U1 RNA (12), an
RNA polymerase II transcript, and to the vesicular stomatitis virus leader RNA
(13). It appears that the 3'-oligouridylate tail of these small RNAs is required
forinteraction with the SS-Bprotein (7, 8, 10). The fact that SS-B/La isassociated
with the precursors of 5S RNA and tRNA but not with their corresponding
mature species has been taken to imply that it may have a role in the maturation
ofthese RNAs (3).
We have previously shown (14) that there are two protease-resistant domains
in SS-B from HeLa cells. These domains are ^-28 and 23 kD and have been
provisionally called the X and Y domains, respectively. Domain X is rich in
methionine but lacks phosphorylated amino acid residues, whereas domain Y
contains little methionine but all of the detectable phosphorylated amino acids.
The phosphorylated domain Y is not required for RNA binding, and UV-
crosslinkingexperiments have demonstrated that the RNA binding site is located
on domain X (15). Most human anti-SS-B autoantibodies react with both struc-
tural domains but some react only with one of the two domains (14). It is clear
that there are at least two distinct autoantibody-reactive epitopes on the native
SS-B protein, each located on a separate structural domain (14). Recent reports
(16-20) have addressed the question as to whether autoantibodies to nuclear
antigens such as SS-B/La, SS-A/Ro, and Sm/RNP are inducible in mice by
immunization with these nuclear antigens. Some workers have been able to
produce true autoantibodies by immunization (17-19), while others have been
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able to obtain only antibodies reactive with heterologous but not autologous
proteins (16). In this study, we have established five anti-SS-B mAbs that were
useful in defining differences between autoantibody-reactive epitopes and epi-
topes recognized by experimentally induced antibodies. The data might provide
insights into the nature ofepitopes on autologous proteins that are target antigens
of spontaneously occurring autoantibodies.
Materials and Methods
Cell Culture and Labeling. HeLa (human), Vero (monkey), R9ab (rabbit), MDBK
(bovine), 3T3 (mouse), BHK-21 (hamster), and PtK2 (rat kangaroo) cells were obtained
from American Type Culture Collection (Rockville, MD) and grown in monolayer cultures
with DMEM containing 10% calf serum at 37°C in a 10% C02 incubator. Mouse S49.1
cells (American Type Culture Collection) were grown as above except in suspension
cultures. Rat 6m2 cell line was supplied by Dr. R. B. Arlinghaus(M . D. Anderson Hospital,
Houston, TX) and was grown in DMEM with 15% calf serum. Cultures were supplemented
with 2.5 jug/ml gentamycin sulfate and used at subconfluent densities. Monolayer cells
were labeled with [12P]orthophosphate (New England Nuclear, Boston, MA) or [s5S]-
methionine (Research Products International Corp., Mount Prospect, IL) at 100,uCi/ml
in phosphate-free medium or methionine-free medium (Flow Laboratories, Inc., McLean,
VA), respectively, each supplemented with 2% calf serum and grown for 16 h. Cells were
washed twice with PBS, harvested by scraping, extracted in Buffer A (150 mM NaCl, 10
mM Tris-HCI, pH 7.2, 0.5% Nonidet P-40); supernatants after centrifugation at 12,000
g for 15 min were used as the source of antigens in immunoprecipitation.
Affinity Column Purification ofSS-B Antigen.
￿
IgG fraction from 10 ml of high titer anti-
SS-B human serum was purified via a DEAE-Sephacel (Pharmacia Fine Chemicals, Upp-
sala, Sweden) column (35 x 2 cm) using conditions described (21). A 100 ml anti-SS-B
affinity column was constructed by covalently crosslinking IgG to Sepharose CL-4B
(Pharmacia Fine Chemicals) with the cyanogen bromide-coupling method (22) except for
the following modifications. The concentration of cyanogen bromide was doubled and
the coupling reaction was carried out in 100 mM sodium phosphate, pH 7.0, for 30 min
at 15°C.
Extracts were obtained from calf thymus glands and fractionated by ammonium sulfate
precipitation as described (14). The 60% ammonium sulfate-soluble fraction of the calf
thymus extract (CTE)' was dialyzed in PBS and subsequently equilibrated with the affinity
column overnight at 8°C. Unbound proteins were washed with 10 column volumes of
PBS and then with 5 volumes of PBS also containing 0.5 M NaCl . Pure SS-B fractions
were eluted with 3 M MgC12, dialyzed in PBS, concentrated with polyethelene glycol
(PEG) 20,000-1 mg/ml, and stored frozen in small aliquots.
Immunization.
￿
6-8-wk-old BALB/c mice were obtained from our own Animal Breed-
ing Facility, Scripps Clinic and Research Foundation. The immunization protocols for
five groups of mice are summarized in Table I. Basically, two types of immunogens were
used: (a) 50-A1 beads (protein A-Sepharose 4B, Pharmacia Fine Chemicals) coated with
bovine SS-B. These were prepared by adding 4 gm protein from the 60% saturated
ammonium sulfate-soluble fraction of CTE to 5 ml high titer human anti-SS-B serum and
50 ml of a 10% suspension of protein A-Sepharose 4B in PBS. The reaction mixture was
incubated for 2 h at 8°C and the beads were washed extensively with PBS, resuspended
to a 20% suspension in PBS, and injected intraperitoneally into mice. (b) 20 ug of gel-
purified 46-kD bovine SS-B protein. The immunogen derived from affinity column-
purified bovine SS-B and further purified via preparative SDS-PAGE and electroelution
(23) was mixed in CFA, and injected intraperitoneally into mice. Mice were bled from the
retrobulbar sinus at several time points and 2 wk after the last injection. Blood was allowed
to clot at room temperature and the serum was recovered and stored at -20'C.
' Abbreviations used in this paper:
￿
BGG, bovine gamma globulin; CTE, calf thymus extract; PEG,
polyethylene glycol.CHAN AND TAN
TABLE I
Summary ofImmunization Protocols
* Protein A-Sepharose 4B beads coated with bovine SS-B/La.
$ Gel-purified 46-kD bovine SS-B/La.
§ All five hybridomas A1-5 were derived from mouse F1 .
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Cell Fusion.
￿
Hybridomas were produced by the fusion of splenocytes to the nonpro-
ducing mouse myeloma P3-X63-Ag8.653 using PEG as described (24) with the following
modifications. Mice with the highest level of anti-SS-B antibodies were selected and they
received two intravenous injections of 200 Ag affinity-purified SS-B 10 d apart. 3 d after
the last immunization, splenocytes (35 x 106) were harvested and fused with myeloma
cells (7 x 106; i.e., 5:1 ratio) in 35% PEG 1450 (Eastman Kodak Co., Rochester, NY) for
1 min. After fusion, cells were diluted in 250 ml of DMEM supplemented with 15% FCS
(HyClone Laboratories, Logan, UT), hypoxanthine, aminopterin, thymidine, glutamine,
gentamycin sulfate, nonessential amino acids, sodium pyruvate, glucose, and 4 x 106/ml
feeder thymocytes from 4-wk-old C3Heb/Fej mice (Animal Breeding Facility, Scripps
Clinic and Research Foundation). The cell suspension was distributed into ten 96-well
tissue culture plates, which were maintained in a humidified, 37°C, 10% C02 incubator.
Wells containing growing hybridomas were screened for Ig production and antibody to
SS-B by ELISA. Initial SS-B ELISA-positive supernatants were further tested by immu-
noblotting and by immunofluorescence using HEp-2 cells as substrate. Hybridomas
producing anti-SS-B were subcloned by limiting dilution.
Immunofuorescence Techniques.
￿
Prefixed HEp-2 cell slides were obtained from Bion,
Park Ridge, IL . Additional cell lines were grown in Lab-Tek tissue culture chambers
(Miles Laboratories Inc., Naperville, IL) following manufacturer instructions, and they
were fixed in a mixture of acetone and methanol (3 :1) at -20'C for 2 min, then air dried.
Mouse sera were tested at dilutions of 1/40 in PBS and hybridoma supernatants were
screened without any dilution . Antibody was detected using fluorescein-labeled affinity-
purified goat antibody to mouse IgA + G + M (H + L) (Kirkegaard & Perry Laboratories,
Inc., Gaithersburg, MD).
ELISA for mAbs and Isotype Analysis.
￿
ELISA for the detection of anti-SS-B mAbs was
established with a standard method as described (25). Affinity-purified bovine SS-B was
used for coating Immulon 2 microtiter plates (Dynatech Laboratories, Inc., Alexandria,
VA) at a concentration of 1 pg/ml in PBS. Plates were incubated at 8 ° C for 6 h, blocked
with 0.1 % gelatin overnight, washed with PBS containing 0.05% Tween 20 (PBS-Tween),
and incubated for 1 .5 h with undiluted culture supernatants (100 u]). After incubation
and washes with PBS-Tween, Ig was detected by peroxidase-conjugated goat anti-mouse
IgG + M reagents (Caltag Laboratories, So. San Francisco, CA) and the substrate 2,2'-
azinobis(3-ethylbenzthiazoline sulfonic acid) as described (25).
For the determination of Ig concentration, culture supernatants were diluted 50-fold
with serum diluent containing 0.75 mg/ml bovine gamma globulin (BGG) and added to
ELISA plates coated with affinity-purified goat anti-mouse IgG + M (Tago Inc., Burlin-
game, CA) at I mg/ml. mAb isotype was determined in a similar manner except using
peroxidase-conjugated goat anti-mouse Ig class, subclass, and light chain-specific reagents
(Caltag Laboratories).
Group
Number of
animals Immunogen Immunization protocols
I 5 Coated beads* Weekly times 12
(B1-B5)
II 10 Protein$ Biweekly times 6
(C1-C10)
III 6 Protein Two times 1 mo apart
IV 4 Coated beads Two times i mo apart
V 44 Coated beads Two times 1 mo apart
(F1-F4)1630
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Sera.
￿
The anti-SS-B/La serum Zewas the Centersfor Disease Control(CDC)(Atlanta,
GA) reference serum (26) and has been shown (14) to contain antibodies reactive with
both X and Y domains of SS-B/La. Normal human sera were obtained from our healthy
laboratory personnel.
Immunoprecipitation and SDS-PAGE Analysis of Labeled Cellular Antigens.
￿
Protein A-
Sepharose-facilitated immunoprecipitation of labeled cellular antigen with antisera or
monoclonals was performed as described (6, 14, 15). Typically, to a 20-40 U1 labeled
extract we added 50,u] BSA (50 mg/ml), 500 Ed Buffer B (50 mM Tris-HCI, pH 7.4, 150
mM NaCl, 5 mM EDTA, 0.5% NP-40, 0.5% sodium deoxycholate, 0.1% SDS), 10 ;.1
rabbit anti-mouse Ig serum (Cederlane Laboratories Ltd., Westbury, NY), 10 U1 mouse
serum or 1 ml hybridoma culture supernatant, and 100 ul of 10% (wt/vol) Protein A-
Sepharose beads in Buffer B. When the mixture contained human serum-positive control
or mouse antisera, the rabbit antiserum was omitted. This suspension was mixed at 4°C
for 1 h. The precipitated Protein A-Sepharose beads were washed five times with 1 ml
ofBuffer B. Proteins were eluted by boiling in Laemmli's sample buffer and analyzed in
SDS-PAGE (27). For RNA analysis, precipitates were extracted with phenol and RNAs
were precipitated with ethanol, and electrophoresed in 7 M urea-polyacylamide gels.
Immunoblot ofSS-B and Fragments.
￿
Immunoblot detection of anti-SS-B antibodies in
human and mouse sera was performed with a standard method (28). '21I-Protein A and
1211-goat anti-mouse a chain were used to detect human and mouse Igs, respectively.
Preparations of cell and tissue extracts and conditions for the generation of protease
partial digests were described in detail elsewhere (14).
Results
Immunization.
￿
Initial immunization protocols (Table I, groups I and II) were
carried out with multiple intraperitoneal injections over a 12-wk period. These
lengthy immunization schedules were selected because we were concerned that
a conserved protein such as SS-B/La might not be a good immunogen and
multiple injections would increase the chance of producing antibody. It was
apparent later that simple immunization protocols such as those of groups III-
V were sufficient in the induction ofmouse anti-SS-B/La antibodies.
Mouse antisera were tested initially by ELISA, immunoblotting, immunofluo-
rescence, and immunoprecipitation with extracts from [s2P]phosphate-labeled
HeLa cells. The resultsare summarized in Table II and Fig. 1 for mouse antisera
obtained 8 wk after the first injection. Although at this time point the mice had
gone through only two-thirds of the immunization protocol, it was clear that
mice BI-5, C4-6, and C9 were producing humoral immune responses to bovine
SS-B and HeLa SS-B. The immunoprecipitation results also indicated that anti-
SS-B antibodies in these mouse sera were IgG since they were bound to protein
A-Sepharose without requiring the rabbit-bridging antibody in the assay. There
were strong correlations when comparisons were made among the reactivities of
mouse antisera in ELISA, immunoblotting (Table II), and immunoprecipitation
(Fig. 1), but the staining in indirect immunoflorescence by antisera varied from
very weak to negative. It was interesting that mice C5, C8, and C10 immunopre-
cipitated a 95-kD HeLa phosphoprotein (Fig. 1), but these antibodies were
apparently not linked inseparably to the SS-B immune response.
When the entire immunization protocol was completed, sera from all 5 mice
in group I and 9 of 10 mice in group II reacted with SS-B by ELISA and
immunoblotting_ These reactivities were confirmed by immunoprecipitation
where both the 48-kD SS-B phosphoprotein and its associated precursor tRNA5
were precipitated (data not shown). Mouse C3 was the only one that did notTABLE II
Reactivities ofMouse Antisera
CHAN AND TAN
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* Mice BI-5 and C1-10 were from Table I, groups Iand II, respectively.
Sera were obtained at 8 wk, two-thirds through the course of the
immunization protocol.
$Purified bovine SS-B was used as coating antigen. Absorbance at 405
nm were taken 2 h after theaddition of substrate.
produce an antibody response to SS-B at the end ofthe immunization protocol.
In subsequent studies with groups III, IV, and V, every mouse produced anti-
SS-B/La antibodies detectable by immunoblotting and ELISA 2 wkafter the last
injection.
In view of the apparent crossreactivity of mouse antisera with bovine and
HeLa SS-B as discussed above, we were interested to determine if the murine
humoral immune response to bovine SS-B could be an autoimmune response in
which antibodies were reactive with autologous protein. In Fig. 2, immunoblot-
tings of SS-B from different species were compared using human SS-B serum Ze
and mouse antisera from B5 and C4, which had the highest titer anti-SS-B
antibody in groups I and II, respectively. It was clear that serum Ze reacted with
SS-B from HeLa, mouse, bovine, and rabbit and the mouse antisera reacted with
SS-B from human, bovine, and rabbit but not SS-B from mouse. This showed
that the humoral immune responses of the mice were directed to bovine SS-B
antigenicdeterminants that were also present in HeLa and rabbit SS-B but absent
in mouse SS-B.
Cell Fusion.
￿
Six earlier fusions were carried out with splenocytes from differ-
ent mice immunized with SS-B. Numerous Ig-secreting hybridomas were ob-
tained but none reacted with SS-B. In the last and successful fusion, 35 X 106
cells were recovered from the spleen and fused with myeloma cells at a ratio of
5:1 . Hybridoma supernatants from 193 wells were tested for anti-SS-B activity
by ELISA. Seven positive supernatants were initially detected and were further
tested by immunoblotting with HeLa cell extracts. Five of the seven clones
reacted with the 48-kD SS-B protein. These five positives were subcloned twice
Mouse sera* ELISA ODD Immunoblotting
HeLa extract
B1 2.58 +
B2 3.41 +
B3 3.84 +
B4 3.93 +
B5 4.06 +
C1 0.09 -
C2 0.10 -
C3 0.07 -
C4 1.40 ' +
C5 1.10 +
C6 0.98 +
C7 0.03 -
C8 0.04 -
C9 0.79 +
C10 0.12 -1632
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FIGURE 1 .
￿
Immunoprecipitation of extracts from [12Plphosphate-labeled HeLa cells with
mouse antisera andserumZe . (Top) Immunoprecipitate digested with RNase and the remaining
phosphoprotein analyzed on standard SDS-PAGE. (Bottom) RNAs of the immunoprecipitates
were phenol extracted, ethanol precipitated, and analyzed on 7M urea/10% polyacrylamide
gel. There was good correlation between the amount of 48-kD protein and pre-tRNA
precipitated. B1-5 and CI-10 mouse antisera were obtained from group I and II mice used
for immunization with bovine SS-B . NMS, normal mouse serum .
by limiting dilution and labeled A1 to A5 . All five subcloned mAbs were found
to be IgG 1K.
Specificity of mAbs.
￿
When the supernatants from the subcloned hybridomas
were allowed to react with HeLa cell extracts in immunoblotting (Fig . 3A), all
five mAbs reacted with the 48-kD SS-B protein . The human serum Ze reacted
strongly with the 48-kD protein and a spontaneous 43-kD degradation product,CHAN AND TAN
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FIGURE 2 .
￿
Immunoblotting analysis of the reactivities of mouse antisera and human serum
Ze using extracts from HeLa cell, S49.1 cell (mouse), calf thymus gland, and rabbit thymus
acetone powder . It was apparent that both mouse sera B5 and C4 reacted with SS-B from
HeLa, calf thymus, and rabbit thymus but were not reacting with SS-B from mouse 549.1
cells .
FIGURE 3 .
￿
Immunoblotting analysis of the reactivities of mAbs using HeLa cell extract (A)
and HeLa cell extract partially digested with S.a.V8 protease (B).
whereas the mAbs did not react with the 43-kD fragment. In further blotting
experiments not shown here, A1 and A2 reacted with the spontaneous 43-kD
fragment but the intensity was always lower than that of human serum . In
addition to the reactivity with the 48-kD SS-B protein, A3 and A4 also reacted
with additional HeLa proteins of 105 and 55 kD, respectively . On the other
hand, A1, A2, and A5 appeared to be highly specific for the HeLa SS-B protein .1634
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FIGURE 4 . Immunoprecipitation of ["Pl-
phosphate-labeled HeLa cell extract with
mouse mAbs and serum Ze . RNA wasextracted
from the immunoprecipitate with phenol, pre-
cipitated with ethanol, and analyzed on 7 M
urea/8% polyacrylamide gel .
We have previously shown (14) that there are two protease-resistant domains
in HeLa SS-B based on the reactivity with human sera . S.a .V8 protease can
reproducibly cut HeLa SS-B protein to generate fragments X/X'/X" (28/29/30
kD) and Y/Y' (23/24 kD) derived from domains X and Y, respectively . Fig . 3B
shows the results of the analysis of the fine domain specificity of these mAbs .
A1, A2, A4, and A5 reacted with X/X'/X" fragments of the X domain but their
reactivities varied with respect to different fragments . A3 did not react with
either X or Y fragment . These results suggested that A1, A2, and A3 were
recognizing different epitopes from each other and from A4 and A5, which are
both reactive with the X/X' fragments . Taking into accountthe further reactivity
of A4 with the 55-kD HeLa protein, we concluded that A5 was recognizing a
different epitope from A4 .
Immunoprecipitation of mAbs.
￿
SS-B/La protein is associated with precursor
tRNAs in HeLa cell, and human sera specific for SS-B can immunoprecipitate
not only the SS-B protein but also pre-tRNAs . Fig . 4 shows the urea gel analysis
of the RNA present in the immunoprecipitate between mAbs and extracts from
"'P-labeled HeLa cells . Three of the five anti-SS-B/La mAbs could immunopre-
cipitate pre-tRNAs that appeared to be identical to those ofserum Ze . The band
running around 5.8S/U 1 RNA is apparently nonspecific because it was also
present in the reaction with normal human serum (N) . The same three mAbs
also precipitated the 48-kDphosphoprotein of SS-B as expected (datanot shown) .
A4 and A5, which did not immunoprecipitate RNA or protein, were probably
reacting with epitopes only present in the denatured SS-B protein as demon-
strated in the immunoblot results .CHAN AND TAN
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FIGURE 5 .
￿
Immunofluorescent staining of anti-SS-B antibodies . Bovine MDBK cells were
grownon slides, fixed with acetone/methanol, and stained with serumZe (A)and serum from
the mouse F1 used for the production of hybridomas (B) . Pre-fixed human HEp-2 cells were
stained with same mouse antiserum F 1 (C), with anormal mouseserum (D), with human serum
Ze with antibodies specific forSS-B (E), and murine anti-SS-B mAb A1 (F). mAbs A2 and A3
also gave identical staining pattern as Al and human serum Ze . Original magnification, x
500 .
Immunofluorescence. Fig. 5, B and C, shows the staining patterns of the
antiserum from mouse F1 that was used for the production of these hybridomas.
F1 serum gave fine speckles in the nucleoplasm, which excluded the nucleolus,
and this pattern was identical to that of the CDC human anti-SS-B reference
serum Ze both for MDBK and HEp-2 cells (Fig . 5, A and E) . Normal mouse
serum did not give any staining (Fig. 5D) . As expected from the immunoblotting
ofmouse antisera described above, the F I serum did not give any staining with
mouse 3T3 cells (data not shown) .
Initial examination of the mAbs showed that Al and A2 gave similar patterns1636
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TABLE III
Species-specific Reactivities ofmAbs as Detected by Immunofluorescence
* Cells were grown in Lab-Tek tissue culture chambers and fixed in a mixture of acetone and
methanol (3:1)at -20°C for 2 min.
$ Ze serumis the CDC reference serum foranti-SS-B/La specificity.
of fine nuclear speckles as the human serum with commercial Bion HEp-2 cells
(Fig. 5, E and F), and A3, A4, and A5 did not stain. In view of the positive
immunoblotting results as discussed above, we decided to determine the effect
of other fixation methods on the reactivity of the mAbs. In addition to the
standard acetone/methanol fixation method as outlined in Materials and Meth-
ods, we tried three other methods: (a) 95% ethanol, 0°C, 10 min; (b) 100%
methanol, -20'C, 4 min; (c) acetone/ethanol (1:1), 0'C, 2 min. Al and A2
mAbs and serum Ze gave nuclear staining under all of these conditions, but A4
and A5 did not give any staining with any of these fixation methods. However,
A3 gave fine nuclear speckles when either acetone/methanol or acetone/ethanol
fixation was used. Based on double-staining experiments, the staining patterns
of Al, A2, and A3 were identical to those of human autoantibodies.
Unlike the human SS-B autoantibodies that reacted with SS-B from many
species, the mAbs Al, A2, and A3 react with SS-B in a more species-restricted
manner. As summarized in Table III, Al, A2, and A3 gave typical nuclear-
staining patterns with three human cell lines, a monkey, a rabbit, and a bovine
cell line, but gave no staining with a hamster, a rat, a mouse, and a rat kangaroo
cell line. These data in Table III provide further support for the view that the
mAbs were reacting with epitopes different from those recognized by the human
SS-B autoantibody .
Discussion
Normal BALB/c mice were successfully immunized to produce IgG antibody
to bovine SS-B. These mouse antisera were reactive with SS-B from bovine,
human, and rabbit but did not contain antibodies that were reactive with
homologous SS-B. Five hybridomas secreting IgGlK mAbs to SS-B were cloned
from the spleen cellsofoneofthese immunizedmice. Datafrom immunoblotting,
immunoprecipitation, and immunofluorescence showed that these mAbs reacted
Species Cell line origin
A1 A2
Murine
A3
Immunofluorescence*
mAbs
A4 A5
Human
serum
Ze$
Human HEp-2, larynx + + + - - +
Human HeLa, cervix + + + - - +
Human Raji, Burkitt lymphoma + + + - - +
Monkey Vero, kidney + + + - - +
Rabbit R9ab, lung + + + - - +
Bovine MDBK, kidney + + + - - +
Hamster BHK-21, kidney - - - - - +
Rat 6m2, kidney - - - - - +
Mouse 3T3, fibroblasts - - - - - +
Rat kangaroo PtK2, kidney - - - - - +CHAN AND TAN
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TABLE IV
Characteristics ofmAbs
* Defined by immunoblot reactivities with HeLa SS-B fragments generated by limited
S.a.V8 protease digestion.
$ Human HEp-2 cell as substrate.
g Labeled extracts from HeLa and MDBK cells.
with different SS-B epitopes. As summarized in Table IV, A1, A2, and A3
appeared to recognize epitopes on the native protein as it is constructed in a
ribonucleoprotein particle and thus were able to immunoprecipitate both protein
and RNA and gave nuclear staining in immunofluorescence. A4 and A5 were
negative in both assays but were able to detect the 48-kD protein and the X/X'
fragments in immunoblot; this suggested that they recognized epitopes that were
probably hidden in the native protein but were probably exposed after PAGE
and transfer to nitrocellulose. The species-restricted reactivity of these mAbs
demonstrated the difference between immunogenic epitopes recognized by mAbs
and the more highly conserved epitopes recognized by human autoantibodies.
This is the first report of anti-SS-B/La mAbs capable of precipitating human SS-
B/La particles including the associated RNAs. Previously, a single anti-SS-B
antibody specific to bovine SS-13 was shown to precipitate SS-13 and its RNAs
from Madin-Darby bovine kidney (MDBK) cells (16).
The evidence that immunogenic epitopes recognized by mAbs A1-5 are not
the targets of human autoantibodies is supported by additional evidence from
blocking experiments showing that human serum Ze failed to inhibit mAb
reactivity with SS-B. When either nitrocellulose strips or ELISA wells coated
with SS-13 were first incubated with serum Ze, washed, and later incubated with
different mAbs, reactivities of mAbs were not inhibited (data not shown). The
reciprocal blocking experiment of human SS-B sera by mAbs also showed no
inhibition .
The highly conserved nature of the SS-B/La epitopes recognized by human
autoantibodies is by no means unique to this autoantigen-antibody system. Most
if not all of the systemic rheumatic disease-associated autoantibodies are directed
to ubiquitous cellular components such as DNA, histories, ribosomes, Sm/RNP,
Sc 1-70 (DNA Topoisomerase 1), RNA polymerase 1, PCNA/cyclin (auxiliary
protein of DNA polymerase S), and U3-RNP, which subserve important functions
in eukaryotic cells.
Published data show that human autoantibodies are able to inhibit many of
these cellular functions where they have been tested. Such examples include
inhibition of precursor mRNA splicing (29-31), relaxation of supercoiled DNA
(32), transcription of ribosomal RNA (33), and aminoacylation of transfer RNAs
Antibody Subclass HeLa im-
munoblot
Domain
specificity*
Cell
staining
Immuno-
precipita-
tion4
Al IgGla + Domain X + +
A2 IgGIK + Domain X + +
A3 IgGlrz + + +
A4 1gGlcc + Domain X - -
A5 IgGlcc + Domain X - -1638
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(Dang, C. V., E. M. Tan, and J. A. Traugh, submitted for publication). Such
information, together with the data provided in the current experiments, has
led us to consider the possibility that the conserved epitopes recognized by
human autoantibodies might also be the functional or active sites of these
intracellular proteins. Recent experimentscarriedout in collaboration with other
laboratories provide preliminary evidence to support this hypothesis. Human
autoantibody to PCNA/cyclin was shown to recognize different epitopes from
two immunization-induced murine mAbs and from rabbit antibody to a synthetic
NH2-terminal peptide of PCNA (34). In an in vitro assay system for demonstrat-
ing auxiliary protein-dependent DNA polymerase 8. function, only the human
autoantibody inhibited function (Tan, C. K., K. F. Sullivan, E. M. Tan, K. M.
Downey, A. G. So, submitted for publication). In another study, human autoan-
tibody to threonyl-tRNA synthetase obtained from a patient with polymyositis
inhibited the catalytic threonyl charging activity, whereas an experimentally
induced rat antibody to the purified enzyme did not (Dang, C. V., et al.,
submitted for publication). It thus appears that the conserved epitopes on many
ubiquitous intracellular proteins that invoke autoimmune responses might also
be the active or catalytic sites of these molecules. If this proves generally to be
the case, elucidation of the mechanism whereby these epitopes are rendered
immunogenic might provide insights into certain aspects of the autoimmune
process.
Summary
SS-B/La, an ubiquitous nuclear protein of 46-48 kD, is a target antigen of
autoantibodies in SLE and Sjogren's syndrome and is involved in the maturation
of RNA polymerase III transcripts such as 5S RNA and tRNAs. We have
previously shown (14, 15) that SS-B consists oftwo protease-resistant domains of
23 and 28 kD, with the latter containing the RNA binding site. The epitopes of
SS-B/La reactive with human autoantibodies are conserved among several mam-
malian species examined. BALB/c mice immunized with affinity-purified calf
thymus SS-B produce IgG anti-SS-B/La antibodies, which reacted with bovine,
human, and rabbit SS-B but not with mouse SS-B/La. The spleen of a mouse
with the highest antibody titer was selected for fusion with P3 myeloma. Five
IgG1 K mAbs (Al-5) were selected by ELISA and immunoblotting. All except
A3 reacted with the 28-kD domain. Al, A2, and A3 were capable of immuno-
precipitating the 48-kD SS-B protein and its associated RNAs. Al, A2, and A3
also gave fine nuclear speckled staining on human, monkey, bovine, and rabbit
cells that was similar in appearance to that with human autoantibodies, but in
contrast to staining with human autoantibodies, they did not stain cells from rat,
mouse, or rat kangaroo. It appears that human autoantibodies target highly
conserved epitopes that can be distinguished from epitopes recognized by im-
munization-induced murine mAbs. Taken together with other data, it appears
that human autoantibodies may be recognizing epitopes that are active or
catalytic sites ofmolecules subserving important cellular functions.
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